ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Zynerba Pharmaceuticals Inc (ZYNE) Report Updated: Apr 22, 2017 | Print This Page

Get more stock ratings by Louis Navellier

Zynerba Pharmaceuticals Inc (ZYNE)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Pharmaceuticals
Competitors: ASMB,AKAO,CORT,HSKA

Stock Analysis

Rating: Monthly View

A
B
C
D
F
April May June July August September October November December January February March

Rating: Weekly View

This Week: B down downgrade
Last Week: A same upgrade
Two Weeks Ago: B up no change
service keys

Zynerba Pharmaceuticals Inc© quotemedia

Company Profile